Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Sitagliptin improves kidney function in type 1 diabetes
Last updated July 12, 2026
Key finding
UACR improved from 7.27 ± 2.41 to 1.32 ± 0.31 mg/mmol (p < 0.001).
This study evaluated the impact of sitagliptin on diabetic nephropathy in adolescents with type 1 diabetes, finding significant improvements in several metabolic parameters.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the impact of sitagliptin on diabetic nephropathy in adolescents with type 1 diabetes, finding significant improvements in several metabolic parameters.
Clinical relevance
Diabetic nephropathy is a serious complication of diabetes that can lead to kidney failure. By demonstrating that sitagliptin can improve key markers of kidney health and glycemic control, this study highlights a potential therapeutic option for adolescents with type 1 diabetes, which may help prevent long-term complications.
Keep in mind
Limited sample size may affect generalizability. Short duration of follow-up may not capture long-term effects. Control group showed no significant changes, indicating potential limitations in comparison.
Published in
Journal Reference
Publication details and source links for this paper.
Nancy SE, Eman AI, Manal HE, Marwa ZI, Amal AE. The effect of sitagliptin on diabetic nephropathy in adolescents with type 1 diabetes: a randomized controlled trial. Diabetologia. 2024;67(12):2637-2649. doi:10.1007/s00125-024-06265-7
Main Effects
Urinary albumin/creatinine ratio improved from 7.27 ± 2.41 to 1.32 ± 0.31 mg/mmol (p < 0.001).
SDF-1 levels decreased from 3.58 ± 0.73 to 1.99 ± 0.76 ng/ml (p < 0.001).
Total daily dose of insulin decreased significantly.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Control (AHCL only), Sitagliptin and SDF-1, Urinary albumin-to-creatinine ratio, Change in insulin-to-carbohydrate ratio, and 5 more.
This study contributes evidence to
Primary intervention
Control (AHCL only)
Primary outcomes
- SDF-1
- Urinary albumin-to-creatinine ratio
- Change in insulin-to-carbohydrate ratio
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
10
Evidence pairs
10
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
10
Evidence pairs
187
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 10 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
DPP-4 Inhibitors and CGM Time in Range
Related evidence
Evidence relationship
DPP-4 Inhibitors and Glucose Variability
Save evidence
Evidence relationship
DPP-4 Inhibitors and Kidney Function
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Urinary albumin-to-creatinine ratio
Control (AHCL only) → Urinary albumin-to-creatinine ratio
Control (AHCL only) → Urinary albumin-to-creatinine ratio
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerChange in insulin-to-carbohydrate ratio
Sitagliptin → Change in insulin-to-carbohydrate ratio
Sitagliptin → Change in insulin-to-carbohydrate ratio
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerCoefficient of variation
Sitagliptin → Coefficient of variation
Sitagliptin → Coefficient of variation
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPostprandial blood glucose
Sitagliptin → Postprandial blood glucose
Sitagliptin → Postprandial blood glucose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerTotal daily insulin dose
Sitagliptin → Total daily insulin dose
Sitagliptin → Total daily insulin dose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerUrinary albumin-to-creatinine ratio
Sitagliptin → Urinary albumin-to-creatinine ratio
Sitagliptin → Urinary albumin-to-creatinine ratio
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Sitagliptin reduced urinary albumin/creatinine ratio by 5.95 mg/mmol (p < 0.001).
- SDF-1 levels decreased by 1.59 ng/ml (p < 0.001).
- Significant reductions in insulin dosage and improvements in glucose control metrics.
Who this applies to
- Adolescents aged 10-19 with type 1 diabetes.
- Patients experiencing early signs of diabetic nephropathy.
Keep in Mind
- Results may not apply to adults or younger children.
- Further studies are needed to confirm long-term benefits.
- The study did not assess all potential confounding factors.
Between the Lines
- Limited sample size may affect generalizability.
- Short duration of follow-up may not capture long-term effects.
- Control group showed no significant changes, indicating potential limitations in comparison.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and Glucose Variability, DPP-4 Inhibitors and CGM Time in Range.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
DPP-4 Inhibitors → Glucose Variability
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceMedications
DPP-4 Inhibitors → CGM Time in Range
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
CGM Time in Range Evidence Hub
All studies measuring CGM Time in Range
2 studies
outcome_hubMeasures CGM Time in Range as a key outcome.
DPP-4 Inhibitors Evidence Hub
All studies on DPP-4 Inhibitors
2 studies
intervention_hubContributes to DPP-4 Inhibitors evidence base.
Glucose Variability Evidence Hub
All studies measuring Glucose Variability
2 studies
outcome_hubMeasures Glucose Variability as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Sitagliptin and Coefficient of variation
Intervention: SitagliptinOutcome: Coefficient of variation
2 results
All studies on Sitagliptin and Time in range
Intervention: SitagliptinOutcome: Time in range
2 results
All studies on Sitagliptin
Intervention: Sitagliptin
2 results
All studies measuring Coefficient of variation
Outcome: Coefficient of variation
2 results
All studies measuring Time in range
Outcome: Time in range
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does DPP-4 Inhibitors improve cgm time in range?
Strong Evidence
DPP-4 Inhibitors may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors improve glucose variability?
Strong Evidence
DPP-4 Inhibitors may improve Glucose Variability.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Coefficient of variation
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors improve kidney function?
Moderate Evidence
DPP-4 Inhibitors appears to improve Kidney Function.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Urinary albumin-to-creatinine ratio
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does DPP-4 Inhibitors improve insulin resistance?
Emerging Evidence
Current evidence does not show a clear benefit of DPP-4 Inhibitors for Insulin Resistance.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Total daily insulin dose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Acarbose may improve glycemic variability compared to sitagliptin.Closed-loop therapy enhances glycemic control in type 2 diabetes.Simplified meal announcement maintains glucose control in type 1 diabetes.Acute exercise improves long-term glycemic control in older adults.Mediterranean diet may improve insulin response in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.